- Home
- PLBY vs KPTI Comparison
PLBY vs KPTI Comparison
Compare PLBY & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLBY | KPTI |
|---|---|---|
| Founded | 1953 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 172.6M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | PLBY | KPTI |
|---|---|---|
| Price | $1.58 | $5.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $3.00 | ★ $15.33 |
| AVG Volume (30 Days) | 773.7K | ★ 1.2M |
| Earning Date | 03-16-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $120,928,000.00 | ★ $146,067,000.00 |
| Revenue This Year | $9.17 | N/A |
| Revenue Next Year | $7.10 | $46.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.13 | 0.57 |
| 52 Week Low | $0.91 | $3.51 |
| 52 Week High | $2.75 | $10.99 |
Technical Indicators
Market Signals| Indicator | PLBY | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 39.37 | 30.03 |
| Support Level | $1.56 | $3.93 |
| Resistance Level | $1.99 | $6.96 |
| Average True Range (ATR) | 0.12 | 0.88 |
| MACD | -0.02 | -0.39 |
| Stochastic Oscillator | 4.60 | 11.14 |
Price Performance
Historical ComparisonAbout PLBY PLBY Group Inc.
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).